- Global Pharma News & Resources

NDRI Elects David M. Albert to the Board of Directors

Philadelphia-based National Disease Research Interchange (NDRI) announces that it has elected to its Board of Directors David M. Albert J.D., Director of Strategy, Emerging Business & Venture Capital Group of Cozen O’Connor. Elected on November 2 to a three-year term, Albert will bring his experience and insight to the nation’s leading source of human organs, cells and tissues for research.

This press release features multimedia. View the full release here:

David M. Albert elected to NDRI Board of Directors (Photo: Business Wire)

Albert is a member at Cozen O’Connor where he regularly advises startup companies and companies of all sizes on a variety of issues, including those related to the creation, maintenance, and protection of their intellectual property assets. He is a member of the International Trademark Association (INTA), a member of the National Committee on U.S.-China Relations, and serves on the executive committee of the board of The Welcoming Center for New Pennsylvanians. Prior to attending law school, Albert worked as a program director with the National Committee on U.S.-China Relations and the America-China Society. He received his Bachelor of Arts from Emory University in 1990; his master's degree in International Affairs from Columbia University in 1997 and his J.D. from University of Pennsylvania Law School in 2003.

Albert is a nephew of the late D. Walter Cohen, DDS. Cohen was a long time board member of NDRI, where he also served as Chairman of the Board and Chairman Emeritus. In 2015, the NDRI Board of Directors established the D. Walter Cohen, DDS, Service to Science Award to be presented to an individual whose career exemplifies a commitment of service to science commensurate with that of Dr. Cohen. In early 2018, Dr. Cohen and leadership of NDRI presented the award to Dr. Francis Collins, Director of the National Institutes of Health.

Mary J.C. Hendrix, PhD, Chair of the NDRI Board and President of Shepherd University, shared, “We are thrilled to welcome David to the NDRI Board of Directors. His professional experience and personal commitment to the advancement of research will contribute to the growth and impact of NDRI.”

Bill Leinweber, NDRI’s President and Chief Executive Officer, “We look forward to working with David and are grateful for his commitment and service to NDRI.”

About NDRI

The National Disease Research Interchange (NDRI) is the nation’s leading source of human tissues, cells and organs for scientific research. A not-for-profit 501 (c) (3) organization founded in 1980, NDRI is funded in part by the National Institutes of Health, public and private foundations and organizations, pharmaceutical and biotechnology corporations. NDRI is a 24/7 operation that partners with a nationwide network of over 130 tissue source sites (TSS), including organ procurement organizations (OPOs), tissue banks, eye banks, and hospitals. The TSS, are distributed throughout the USA, in 45 states, with concentrations in major metropolitan areas on both the east and west coasts. Their wide geographic distribution allows NDRI to provide biospecimens from donor populations with diverse demographics and also facilitates the timely and efficient provision of fresh tissues directly to researchers across the U.S. and around the world. By serving as the liaison between procurement sources and the research community, NDRI is uniquely positioned to support breakthrough advances and discoveries that can affect advances in the treatment and cure of human diseases.

View source version on

Editor Details

Last Updated: 12-Nov-2018